Fred Hutchinson Cancer Research Center's latest findings on cancer immunotherapies, CRISPR for blood disorders, stem cell transplantation and insights on the immune system and cancer will be featured at the 60th annual meeting of the American Society of Hematology, which will be held Dec. 1-4 in San Diego. See highlights below.
ASH PRESS BRIEFING
This year's ASH press program will include a press briefing, "CAR T-Cell Therapies: New Research and Updates from Pivotal Trials," featuring Fred Hutch research on a combination therapy for chronic lymphocytic leukemia (more details below). The briefing will take place at 11:30 a.m. PST, Saturday, Dec 1, in Room 23 of the San Diego Convention Center. It is open to all media registered to attend the meeting. More details will be available in an ASH press release to be distributed at the briefing.
CAR T-CELL THERAPY
With the success of CAR T-cell therapies for some blood cancers, Fred Hutch physician-scientists are taking a closer look at characteristics and outcomes of patients who have received the therapy with the aim of making the therapy work better for more people. Other CAR T-cell therapy work featured at this year's meeting includes taking a deep dive into how the cells behave and early findings on a new CAR T for multiple myeloma.
GENE THERAPY
STEM CELL TRANSPLANTATION
ON THE HORIZON
Other notable experts and newsy topics being presented at ASH:
###
Note: Fred Hutch and its scientists who contributed to these discoveries may stand to benefit from their commercialization. See links above to ASH abstracts for more details on individual researchers' disclosures.
The clinical trials referenced above involve investigational products and/or therapies that have not been approved for commercial marketing by the U.S. Food and Drug Administration or any other regulatory authority. Results may vary and encouraging results from early stage clinical trials may not be supported in later stage clinical trials. No conclusions should be drawn from the information in this report about the safety, efficacy, or likelihood of regulatory approval of these investigational products and/or therapies.
Media Contact:
Molly McElroy
O: 206.667.2210
M: 206.941.8146
mwmcelro@fredhutch.org
At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutch's pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nation's first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Women's Health Initiative and the international headquarters of the HIV Vaccine Trials Network.